Company Overview: Silence Therapeutics plc

Industry & Focus:
Silence Therapeutics plc is a biotechnology company specializing in the discovery and development of innovative therapeutic molecules that incorporate short interfering RNA (siRNA). The company’s primary goal is to create targeted treatments that inhibit the expression of specific genes involved in diseases with significant unmet medical needs.

Key Programs & Clinical Trials:

• Divesiran (SLN124):

  • Evaluated in the SANRECO Phase 2 clinical trial for polycythemia vera (PV).
  • Positive interim results from Phase 1 show substantial reduction in phlebotomy requirements and lowered hematocrit (HCT) levels in PV patients.
  • First subject dosed in Phase 2 as of December 2024.
  • U.S. FDA granted Fast Track and orphan drug designations for PV.
  • European Commission granted orphan drug designation for PV in Europe.

• Zerlasiran (SLN360):

  • Conducted in Phase 1 and Phase 2 clinical trials, shown to lower lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular disease (ASCVD).
  • No major safety concerns reported and positive feedback from FDA and European Medicines Agency regarding Phase 3 cardiovascular outcomes study.
  • Engaged in discussions for potential Phase 3 development and commercialization partnerships.

Financial & Operational Highlights (2024):
While specific figures like revenue, number of customers, or total employee count are not provided, the company is actively progressing its clinical development pipeline, as evidenced by the advancement of multiple therapies and regulatory designations.

Company Size & Market Data (as of April 21, 2025):

• Outstanding Shares: 141,690,850 ordinary shares (including ADSs).
• Market Capitalization: Approximately $737.9 million based on a closing stock price of $19.00 as of June 28, 2024.
• Employees: The company has a small, specialized staff, with key executives such as the President & CEO, CFO, and Head of R&D. Exact employee count is not specified.

Summary:
Silence Therapeutics is focused on innovative siRNA-based therapies aimed at serious unmet medical needs, with promising clinical data and strategic regulatory milestones achieved in 2024. The company is publicly traded on Nasdaq via its American Depositary Shares (ADS), with a market value of nearly $738 million, and maintains a core team of senior executives and directors experienced in biotech, pharmaceuticals, and life sciences.